Advertisement
Singapore markets closed
  • Straits Times Index

    3,176.51
    -11.15 (-0.35%)
     
  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • FTSE 100

    7,834.73
    -42.32 (-0.54%)
     
  • Bitcoin USD

    64,823.33
    +3,208.83 (+5.21%)
     
  • CMC Crypto 200

    1,333.64
    +21.02 (+1.63%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • Dow

    37,775.38
    +22.07 (+0.06%)
     
  • Nasdaq

    15,601.50
    -81.87 (-0.52%)
     
  • Gold

    2,399.10
    +1.10 (+0.05%)
     
  • Crude Oil

    83.08
    +0.35 (+0.42%)
     
  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,547.57
    +2.81 (+0.18%)
     
  • Jakarta Composite Index

    7,087.32
    -79.50 (-1.11%)
     
  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

Will All End Well for This Popular Reddit Biotech?

Will All End Well for This Popular Reddit Biotech?

On June 28, shares of Cel-Sci (NYSEMKT: CVM) plunged nearly 70% peak-to-trough before recovering. The reason behind the wild price action couldn't be more obvious -- the company's pivotal phase 3 study involving its Multikine immunotherapy did not meet its primary endpoint of improving the overall survival (OS) of head and neck cancer patients. Cel-Sci had been extremely popular among traders of the r/WallStreetBets community due to its short interest -- standing as high as 24% before the data release.